Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


De novo design of self-assembling helical protein filaments.

Shen H, Fallas JA, Lynch E, Sheffler W, Parry B, Jannetty N, Decarreau J, Wagenbach M, Vicente JJ, Chen J, Wang L, Dowling Q, Oberdorfer G, Stewart L, Wordeman L, De Yoreo J, Jacobs-Wagner C, Kollman J, Baker D.

Science. 2018 Nov 9;362(6415):705-709. doi: 10.1126/science.aau3775.


Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.

Kramer RM, Archer MC, Orr MT, Dubois Cauwelaert N, Beebe EA, Huang PD, Dowling QM, Schwartz AM, Fedor DM, Vedvick TS, Fox CB.

Int J Nanomedicine. 2018 Jun 26;13:3689-3711. doi: 10.2147/IJN.S159839. eCollection 2018.


Lyophilization of an Adjuvanted Mycobacterium tuberculosis Vaccine in a Single-Chamber Pharmaceutical Cartridge.

Barnes V L, Fedor DM, Williams S, Dowling QM, Archer MC, Cloutier S, Parker S, Vedvick TS, Fox CB, Kramer RM.

AAPS PharmSciTech. 2017 Aug;18(6):2077-2084. doi: 10.1208/s12249-016-0688-7. Epub 2016 Dec 20.


Particle Sizing of Nanoparticle Adjuvant Formulations by Dynamic Light Scattering (DLS) and Nanoparticle Tracking Analysis (NTA).

Chan MY, Dowling QM, Sivananthan SJ, Kramer RM.

Methods Mol Biol. 2017;1494:239-252.


Quantitative measurement of Toll-like receptor 4 agonists adsorbed to Alhydrogel(®) by Fourier transform infrared-attenuated total reflectance spectroscopy.

Dowling QM, Schwartz AM, Vedvick TS, Fox CB, Kramer RM.

J Pharm Sci. 2015 Feb;104(2):768-74. doi: 10.1002/jps.24180. Epub 2014 Sep 19.


Working together: interactions between vaccine antigens and adjuvants.

Fox CB, Kramer RM, Barnes V L, Dowling QM, Vedvick TS.

Ther Adv Vaccines. 2013 May;1(1):7-20. doi: 10.1177/2051013613480144.


Cryogenic transmission electron microscopy of recombinant tuberculosis vaccine antigen with anionic liposomes reveals formation of flattened liposomes.

Fox CB, Mulligan SK, Sung J, Dowling QM, Fung HW, Vedvick TS, Coler RN.

Int J Nanomedicine. 2014 Mar 11;9:1367-77. doi: 10.2147/IJN.S56582. eCollection 2014.


Modulating potency: Physicochemical characteristics are a determining factor of TLR4-agonist nanosuspension activity.

Dowling QM, Sivananthan SJ, Guderian JA, Moutaftsi M, Chesko JD, Fox CB, Vedvick TS, Kramer RM.

J Pharm Sci. 2014 Mar;103(3):879-89. doi: 10.1002/jps.23868. Epub 2014 Jan 24.


Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization.

Orr MT, Kramer RM, Barnes L 5th, Dowling QM, Desbien AL, Beebe EA, Laurance JD, Fox CB, Reed SG, Coler RN, Vedvick TS.

J Control Release. 2014 Mar 10;177:20-6. doi: 10.1016/j.jconrel.2013.12.025. Epub 2013 Dec 29.


In vitro evaluation of TLR4 agonist activity: formulation effects.

Misquith A, Fung HW, Dowling QM, Guderian JA, Vedvick TS, Fox CB.

Colloids Surf B Biointerfaces. 2014 Jan 1;113:312-9. doi: 10.1016/j.colsurfb.2013.09.006. Epub 2013 Sep 19.

Supplemental Content

Loading ...
Support Center